Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?

Figures & data

Table 1 Overview of SURPASS Trials (25–29)

SURPASS	Inclusion Criteria	N	Duration (Weeks)	Mean Duration of T2DM (Years)	Mean Baseline HbA1c (%)	Treatment Groups (N)	Change in Mean HbA1c	Change in Mean Body Weight (%)	Overall Treatment Discontinuation n (%)
1	Naive to injectable ADAs	478	40	4.7	7.9	TZP 5mg (121)	−1.87	−7.9	7 (5.7)
						TZP 10mg (121)	−1.89	−9.3	9 (7.4)
						TZP 15 mg (121)	−2.07	−11	18 (14.8)
						Placebo (115)	+0.04	−0.9	16 (13.9)
2	T2DM inadequately controlled on metf	1879	40	8.6	8.2	TZP 5mg (471)	−2.09	−8.5	19 (4)
						TZP 10mg (469)	−2.37	−11	27 (5.7)
						TZP 15mg (470)	−2.46	−13.1	24 (5.1)
						Semaglutide 1 mg (469)	−1.86	−6.7	26 (5.5)
3	Insulin naive, metf or metf and SGLT2i	1444	52	8.4	8.1	TZP 5mg (359)	−1.93	−8.1	26 (7.2)
						TZP 10mg (361)	−2.20	−11.4	40 (11)
						TZP 15mg (359)	−2.37	−13.9	19 (5.2)
						Insulin Degludec (365)	−1.34	+2.7	34 (9.3)
4	Increased risk of CVD	2002	52	10.5	8.5	TZP 5mg (329)	−2.24	−8.1	21 (6.3)
						TZP 10mg (330)	−2.43	−10.7	11 (3.3)
						TZP 15mg (338)	−2.58	−13.0	9 (2.6)
						Insulin Glargine (1005)	−1.44	+2.2	52 (5.1)
5	Insulin dependent T2DM	475	40	13.3	8.3	TZP 5mg (116)	−2.23	−6.6	7 (6)
						TZP 10mg (119)	−2.59	−8.9	4 (3.3)
						TZP 15mg (120)	−2.59	−11.6	10 (8.3)
						Placebo (120)	− 0.93	+1.7	3 (2.5)

Abbreviations: ADA, antidiabetic agents; T2DM, Type 2 diabetes mellitus; Metf, metformin; SGLTi, sodium-glucose co-transporter 2 inhibitors; TZP, Tirzepatide; CVD, cardiovascular disease.